Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine ...

The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr.

Two of President Trump’s top health nominees are on a collision course as the incoming administration faces a crucial ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea, marking a major shift in the treatment ...

Health Care Health Care   The Big Story MAHA leaders heading for clash over GLP-1 drugs Two of President-elect Trump’s top ...

On Christmas Day, Elon Musk turned heads with a decadent photo by his tree. Dressed head-to-toe in a Santa costume, he ...